Zebrafish Ovarian Cancer Models

Introduction Model Details Phenotypic Evaluation Applications Study Examples

Introduction

Ovarian cancer is the leading cause of gynecologic cancer mortality, with epithelial ovarian cancer (EOC) accounting for over 90% of cases. High-grade serous ovarian carcinoma (HGSOC) is the most common and aggressive subtype, typically diagnosed at advanced stages with extensive peritoneal dissemination. Key pathological features include tumor cell shedding into the peritoneal cavity, ascites formation, omental metastasis, and hematogenous spread. Major genetic alterations involve TP53 mutation, BRCA1/2 deficiency, homologous recombination defects, and copy number alterations. Clinical symptoms are often subtle and nonspecific, including abdominal distension, bloating, pelvic pain, early satiety, and urinary urgency, contributing to late-stage diagnosis.

Current standard therapy includes cytoreductive surgery combined with platinum-based and taxane-based chemotherapy. Maintenance therapy with PARP inhibitors and anti-angiogenic agents such as bevacizumab has improved outcomes in select populations. However, approximately 80% of patients experience relapse, and the development of platinum resistance remains a critical clinical challenge. Other major research obstacles include extensive tumor heterogeneity, peritoneal and hematogenous metastatic spread, and the lack of rapid functional assays for predicting individual patient treatment response. Zebrafish ovarian cancer models provide a fast, scalable in vivo platform for evaluating tumor cell dissemination, peritoneal-like metastasis, drug sensitivity, and personalized treatment strategies.

Why Zebrafish?

Real-time Tracking: Transparent larvae allow real-time tracking of tumor cell dissemination and metastasis.
Rapid Testing: Short assay window supports rapid drug sensitivity testing within days.
PDX Compatible: Small tumor sample requirement enables patient-derived xenograft studies.
High Throughput: High-throughput capacity supports functional precision medicine applications.

Available Zebrafish Disease Models

Our ovarian cancer model portfolio covers cell line xenografts, patient-derived zAvatar models, metastasis models, and vascular reporter-based angiogenesis assays:

Model Name	Induction Method	Features
Ovarian Cancer Cell Line Xenograft Model	Fluorescently labeled human ovarian cancer cell lines, such as SKOV3, OVCAR3, OVCAR8, A2780, or ES-2, are transplanted into zebrafish embryos or larvae.	A practical model for assessing tumor cell proliferation, survival, dissemination, and drug response. Suitable for rapid efficacy screening of chemotherapies, PARP inhibitors, and targeted agents.
Patient-Derived Ovarian Cancer Xenograft (zAvatar) Model	Fresh tumor cells from patient ascites, solid tumor biopsies, or surgical specimens are fluorescently labeled and implanted into zebrafish larvae.	A functional precision medicine platform for predicting individual patient treatment response. Tumor take rate is high, turnaround time is short (approximately 1 week), and the model has been evaluated in co-clinical studies.
Ovarian Cancer Metastasis and Dissemination Model	Metastatic ovarian cancer cells or patient-derived tumor cells are implanted into zebrafish embryos, and dissemination is tracked by fluorescence imaging.	Supports quantitative analysis of tumor cell migration, extravasation, and metastatic colonization. Suitable for evaluating anti-metastatic compounds and studying mechanisms of peritoneal spread.
Ovarian Cancer Angiogenesis Xenograft Model	Ovarian cancer cells are implanted into vascular reporter zebrafish lines, such as Tg(fli1:EGFP) or Tg(kdrl:EGFP), followed by live imaging of vascular response.	Enables assessment of tumor-induced angiogenesis, vessel remodeling, and anti-angiogenic drug activity. Suitable for evaluating bevacizumab and other VEGF/VEGFR pathway inhibitors.

Phenotypic Evaluation

Drug Response and Safety

Reduction in tumor burden
Inhibition of dissemination or angiogenesis
Larval survival and gross morphology
Basic toxicity readouts, including edema and developmental delay

Tumor Growth

Tumor fluorescence area or intensity
Tumor cell expansion over time
Tumor growth inhibition after treatment

Metastasis and Dissemination

Number of disseminated tumor foci
Migration distance from implantation site
Extravasation and colonization pattern

Angiogenesis

Tumor-induced vessel sprouting
Peritumoral vessel density
Inhibition of vascular response after treatment

Key Applications

In Vivo Drug Screening: In vivo ovarian cancer drug screening for chemotherapy, PARP inhibitors, anti-angiogenic agents, and combination regimens.
Functional Precision Medicine: Functional precision medicine using patient-derived zAvatar models to predict individual treatment response.
Metastasis Studies: Metastasis and peritoneal dissemination studies using live fluorescence imaging of tumor cell behavior.
Anti-angiogenic Evaluation: Anti-angiogenic therapy evaluation in vascular reporter zebrafish lines.
Mechanistic Studies: Mechanistic studies of platinum resistance, BRCA/HRD biology, and metastatic progression in a vertebrate in vivo context.

Study Examples

The authors used a zebrafish xenograft model to assess the effect of docosahexaenoic acid (DHA) on ovarian cancer cell invasion and metastasis. Human ovarian cancer cells were implanted into zebrafish embryos, and the anti-metastatic activity of DHA was evaluated by quantifying tumor cell dissemination. DHA treatment reduced subintestinal vessel invasion and metastasis-related behavior in vivo.

Fig. 1. DHA treatment reduces ovarian cancer cell invasion and metastatic dissemination in zebrafish xenografts (Wang YC, Wu YN, et al. 2016).

This study established zebrafish xenografts as a rapid screening platform for bevacizumab therapy. Patient-derived tumor samples, including ovarian cancer samples, were implanted into zebrafish embryos, and the effects of bevacizumab on tumor growth, angiogenesis, and metastasis were evaluated. The model revealed differential responses to bevacizumab across individual patient samples within a short assay timeframe.

Fig. 2. Zebrafish xenografts reveal patient-specific responses to bevacizumab across ovarian and other solid tumor samples (Rebelo de Almeida C, Mendes RV, et al. 2020).

Accelerate Ovarian Cancer Research with Zebrafish Models

Accelerate ovarian cancer research with zebrafish models designed for rapid in vivo drug efficacy testing, metastasis analysis, angiogenesis assessment, and functional precision medicine applications.

Contact Our Scientists

References

Wang YC, Wu YN, et al. Docosahexaenoic Acid Modulates Invasion and Metastasis of Human Ovarian Cancer via Multiple Molecular Pathways. International Journal of Gynecological Cancer 26(6), 994–1003 (2016).
Rebelo de Almeida C, Mendes RV, et al. Zebrafish xenografts as a fast screening platform for bevacizumab cancer therapy. Communications Biology 3, 299 (2020).

For research use only. Not intended for any clinical use.